secwatch / observer
8-K filed February 2, 2024, 6:59 PM ET ticker ADTX CIK 0001726711
M&A confidence high sentiment neutral materiality 0.40

Aditxt extends Evofem merger timeline; proxy statement filing pushed to April 1, 2024

Aditxt, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aditxt, Inc. amended Second Amendment to Merger Agreement with Adicure, Inc. and Evofem Biosciences, Inc. (effective 2024-01-30).

Action
amendment
Agreement
merger
Counterparty
Adicure, Inc. and Evofem Biosciences, Inc.
Effective
2024-01-30
Exact text from the filing
On January 30, 2024, the Company, Adicure and Evofem entered into the Second Amendment to the Merger Agreement (the “ Second Amendment to Merger Agreement ”) to amend (i) the date of the Parent Loan (as defined in the Merger Agreement) to Evofem to be February 29, 2024, (ii) to change the date by which Evofem may terminate the Merger Agreement for failure to receive the Parent Loan to be February 29, 2024, and (iii) to change the filing date for the Joint Proxy Statement (as defined in the Merger Agreement) to April 1, 2024.
View on SEC.gov

283 material agreements filed in the last 30 days. Browse all material agreements →

Aditxt, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-24-009659
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.